Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
ENROLLING BY INVITATION
NCT07515391
PHASE2
Dapagliflozin Effect on Glucose Variability in Patients Post Bariatric Surgery
Sponsor: Dasman Diabetes Institute
View on ClinicalTrials.gov
Summary
This study evaluates the effect of SGLT-2 inhibitors (dapagliflozin) on the blood glucose excursions by a continuous glucose monitoring system, the incidence of hypoglycemia and hyperglycemia and change in glycated hemoglobin (HbA1c) level in people had bariatric surgery with and without type 2 diabetes.
Key Details
Gender
All
Age Range
21 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2019-10-22
Completion Date
2026-10-22
Last Updated
2026-04-07
Healthy Volunteers
No
Interventions
DRUG
Dapagliflozin 10 MG
Dapagliflozin 10 mg drug will be administered in both arms for 12 weeks.
Locations (1)
Dasman Diabetes Institute
Kuwait City, Dasman, Kuwait